Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib plus salvage chemotherapy for relapsed or refractory ALK-positive systemic anaplastic large cell lymphoma
ChiCTR2000029373Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in anaplastic large cell lymphoma (ALCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective remission ratio. Started Jan 2013; status: recruiting.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on ChiCTR2000029373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029373.